This is an open-label, randomised phase III, multicentre, Italian study designed to
investigate the role of trastuzumab in patients with locally advanced and/or metastatic
breast cancer over expressing HER2 who received a first line chemotherapy containing
trastuzumab. The trial in divided in two studies: 1. The maintenance study will be conducted
in patients not progressing to a first line chemotherapy plus trastuzumab. 2. The 2nd line
study will be conducted in patients progressing to a first line chemotherapy plus
trastuzumab.
Phase:
Phase 3
Details
Lead Sponsor:
Regione Lombardia
Collaborators:
Istituto Clinico Humanitas Mario Negri Institute for Pharmacological Research